FDA investigates two serious adverse events associated with ImprimisRx ’s compounded curcumin emulsion product for injection

FDA investigates two serious adverse events

Source: FDA Center for Drug Evaluation and Research - What's New - November 14, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news